SCHEMBL25533017

SCHEMBL25533017

O=C(OCc1ccccc1)C(CO)C1CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALDH1A1 P00352 5/20 0.47
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 1/20 0.44
ELANE P08246 1/20 0.44
TSHR P16473 2/20 0.43
DPP4 P27487 1/20 0.43
KCNH2 Q12809 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28688698 0.94 CYP3A4 (0.56) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL28677470 0.94 CYP2C19 (0.56) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL11372657 0.86 CYP2C19 (0.50) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL26870465 0.86 ALDH1A1 (0.50) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL23688650 0.82 CYP2C19 (0.47) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL29552854 0.82 CYP2C19 (0.47) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL19285251 0.82 CYP2C19 (0.47) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL8884907 0.81 CYP2C19 (0.46) CYP2C19CYP3A4CYP2C9ALDH1A1TDP1
SCHEMBL7409492 0.80 CYP3A4 (0.54) CYP2C19CYP3A4CYP2C9ALDH1A1KMT2A
SCHEMBL7412438 0.80 CYP3A4 (0.54) CYP2C19CYP3A4CYP2C9ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof SYSTIMMUNE, INC. (US) 2026-03-17 US disclosed
EP-4595978-A1 ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF SystImmune, Inc. (US) 2025-08-06 EP disclosed
CN-120131991-A Anti-human Claudin18.2 antibody-camptothecine drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2025-06-13 CN disclosed
US-20250115679-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. (CN) 2025-04-10 US disclosed
US-20250059296-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF SYSTIMMUNE INC (US) 2025-02-20 US disclosed
CN-117752813-A anti-CD 33 antibodies and anti-CD 33 antibody-drug conjugates and uses thereof 成都百利多特生物药业有限责任公司 2024-03-26 CN disclosed
CN-116212044-A Anti-human Trop2 antibody-camptothecin drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2023-06-06 CN disclosed
US-20230165969-A1 PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2023-06-01 US disclosed
US-20230165969-A1 PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2023-06-01 US disclosed
CN-116120460-A Bispecific antibody-camptothecins drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2023-05-16 CN disclosed
CN-113827736-A Camptothecin drug with high-stability hydrophilic connecting unit and conjugate thereof 四川百利药业有限责任公司 2021-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof IGLV6-57, EGFR, ERBB2 CYP2C19 2353/4885CYP3A4 2638/4885CYP2C9 1969/4885
US-20250115679-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF ANTXR2, PAICS, CD38 CYP2C19 1716/4885CYP3A4 2614/4885CYP2C9 1940/4885
US-20230165969-A1 PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF CFD, DDOST, HEXD CYP2C19 459/4885CYP3A4 1700/4885CYP2C9 648/4885
US-20250059296-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF ANTXR2, PAICS, CD38 CYP2C19 1716/4885CYP3A4 2614/4885CYP2C9 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.